A nticardiolipin (aCL) antibodies and lupus anticoagulant are the main antibodies associated with the antiphospholipid syndrome, which manifests clinically as vascular thrombosis and pregnancy morbidity. 1 aCL antibodies are strongly associated with venous and arterial thrombosis, both in patients with systemic lupus erythematosus (SLE) and in patients without any apparent autoimmune diseases. 2, 3 It is known that aCL antibodies require a serum cofactor, ␤ 2 -glycoprotein I (␤ 2 GPI) or apolipoprotein H, for binding to cardiolipin in vitro. 4 Antibodies to ␤ 2 GPI can be measured directly and were shown to be more specific than aCL antibodies for the clinical manifestations of antiphospholipid syndrome. [5] [6] [7] However, these are mostly retrospective studies and mainly involve patients with SLE.
An association of aCL antibodies with coronary artery disease has been shown in several 8 -13 but not all studies. 14, 15 In the present study, we evaluated the association of aCL and anti-␤ 2 -GPI (a␤ 2 GPI) antibodies with recurrent myocardial infarction (MI) or cardiac death in a large cohort of patients without autoimmune diseases. The patients were participants in the Thrombogenic Factors and Recurrent Coronary Events (Thrombo) study, a multicenter prospective cohort study that examined the risk of different thrombogenic factors for recurrent coronary events. 16 
Methods

Patients
The Thrombo study recruited 1161 patients hospitalized for acute MI (index MI). Serum samples were collected before hospital discharge and at 2 months after the acute event. We conducted our study on the predischarge sera (average time from index MI to discharge 10.9 days, with range of 1 to 31 days). The study included men or women Ն21 years of age with enzyme confirmation of the index MI with symptoms and/or ECG changes consistent with an acute MI. The index MI could be Q-wave or non-Q-wave in type and either a first or a recurrent infarction. Exclusion criteria were coronary artery bypass grafting surgery during the hospital phase of the index MI, malignancy, or severe hepatic, renal, or cerebral disease. 16 
Study Protocol
Baseline demographic data regarding known risk factors for coronary artery disease and recurrent MI were collected in all patients. The patients were followed up by phone and with regular clinic visits. Eighteen patients were lost to follow-up, and they were included in the analysis up to the time of their last contact. The human investigation committees of all the participating hospitals approved the study protocol. Written informed consent was obtained from all study participants.
Measurement of Antibodies
All the tests were done in duplicate with sera stored at Ϫ70°C, and the mean value was obtained. One of the authors performed all the tests in the same laboratory environment. Determination of aCL antibodies was performed by standardized ELISA for both IgG and IgM isotypes (REAADS Medical Products, Inc) with bovine calf serum in the sample diluent as the source of ␤ 2 GPI. Results are expressed as GPL units for the IgG (positive Ն23 GPL) and MPL units for the IgM (positive Ն11 MPL) aCL antibodies, with 1 GPL or MPL unit being equivalent to 1 g/mL of an affinity-purified standard IgG or IgM aCL antibody sample. 17 Determination of IgM and IgG a␤ 2 GPI antibodies was performed by ELISA with irradiated and chemically activated plastic microwell plates containing purified human ␤ 2 GPI (INOVA, Inc). Results are expressed in standardized units, 18 SGU for the IgG (positive Ն20 SGU) and SMU for the IgM (positive Ն20 SMU) a␤ 2 GPI antibodies. All tests met the quality control standards as determined by the manufacturer.
Statistical Analysis
The end points were cardiac mortality and cardiac morbidity with rehospitalization as the result of recurrent nonfatal MI (cardiac 2 GPI antibodies were dichotomized at a cutoff point closest to the 75th percentile, and comparisons of the highest quartile (Q 4 ) versus the lower 3 quartiles (Q 1-3 ) were performed. This dichotomization parallels the analysis of the original Thrombo study and resolves the problem of skewness. The cutoff values for the highest quartile were 12.5 GPL for IgG aCL, 4.1 MPL for IgM aCL, and 2.0 SMU for IgM a␤ 2 GPI antibodies. For IgG a␤ 2 GPI antibodies, values of the 95th percentile were used for analysis rather than the quartile approach because there were only 47 patients with any detectable level of these antibodies. Kaplan-Meier survival analysis was used for estimation of event rates in association with the IgG and IgM aCL and a␤ 2 GPI antibodies. The Cox proportional-hazards survivorship model was used to evaluate the independent contribution of risk variables to outcome events. In the construction of the Cox model, a clinical model was first obtained by including any clinical variable that entered the model at a level of significance Ͻ0.1 after a forward stepwise regression scheme. This approach was used to ensure inclusion of any added contribution to this model from important covariates with borderline levels of significance. Individual medications (as listed in Table 1) were tested in the model one at a time. The SAS statistical program (SAS Institute, Inc) was used for data analysis.
Results
Of the 1161 patients recruited, serum samples were available for testing on 1150. The baseline characteristics for the entire study population and for patients in the highest and lower 3 IgG and IgM aCL antibody quartiles are shown in Table 1 . Race was the only covariate with significantly different frequencies in the high and low quartile distributions of both IgG and IgM aCL antibodies.
During the mean follow-up period of 24.6 months (range 0 to 42 months), a total of 131 recurrent cardiac events (84 cardiac deaths and 47 nonfatal MI) occurred. The group with events was older, with a higher percentage having had a prior MI before the index MI and having hypertension, diabetes mellitus, pulmonary congestion, and ejection fraction Յ30%.
The mean levels and number of patients in the highest quartiles of IgG and IgM aCL and a␤ 2 GPI antibodies in those with and without coronary events are shown in Table 2 . There is a trend for higher IgG aCL and lower IgM aCL antibody levels in patients with than without events (Pϭ0.06 for both). The highest quartiles of IgG aCL and IgM aCL antibodies show a similar trend ( Table 2 ). The IgG and IgM a␤ 2 GPI antibodies did not show a significant association or a meaningful trend with recurrent cardiac events.
Kaplan-Meier survivorship analysis for the IgG and IgM aCL antibodies is shown in the Figure. Patients in the highest quartile of IgG aCL antibodies had a higher coronary event rate than patients in the lower 3 quartiles (Pϭ0.05). A reverse trend was observed for the IgM aCL antibodies (Pϭ0.06).
The risk contributed by aCL antibodies to the Cox model after adjustment for relevant clinical covariates is shown in Table 3 . The variables that entered the clinical model at the 0.1 level of significance were age Ն60 years, prior MI before the index MI, diabetes mellitus, smoking, pulmonary congestion, and ejection fraction Յ30%. In this model, IgG aCL antibodies in the highest quartile of the distribution contributed an independent hazard ratio (HR) of 1.63 (95% CI 1.11 to 2.38; Pϭ0.01) for recurrent coronary events. In contrast, IgM aCL antibodies in the lower 3 quartiles of the distribution contributed an independent HR of 1.76 (95% CI 1.10 to 2.82; Pϭ0.02) for recurrent coronary events.
Because the IgG and IgM aCL antibodies contributed comparable opposite effects, we explored the joint risk for patients in the high-and low-risk partitions of both aCL antibody isotypes. The group of patients with IgM aCL antibodies in the highest quartile and IgG aCL antibodies in the lower 3 quartiles had the lowest risk and was chosen as the reference group. Patients with IgG aCL antibodies in the highest quartile and IgM aCL antibodies in the lower 3 quartiles had higher risks than any other aCL antibody group and 3-fold higher risk than the reference group (Pϭ0.001) ( Table 4) .
The cutoff values for the upper quartiles of the IgG (Ն12.5 GPL) and IgM (Ն4.1 MPL) aCL antibodies are lower than the values that are considered positive in the aCL antibody assay that was used in our study (Ն23 GPL for IgG and Ն11 MPL for IgM aCL antibodies). When the data were analyzed according to the positive values, positive IgG and IgM aCL antibodies were associated with hazard ratios of 2.0 (Pϭ0.01) and 0.8 (Pϭ0.6), respectively. The low number of positive IgG and IgM aCL antibodies in the group of patients with events (Table 2 ) was the main obstacle to the interpretation of these results. The correlation coefficients for aCL and a␤ 2 GPI antibodies by isotype are shown in Table 5 . A moderately strong correlation (rϭ0.50) was present only between IgM aCL and a␤ 2 GPI IgM antibodies.
Discussion
This report represents the largest study to date evaluating the association between aCL and a␤ 2 GPI antibodies and recurrent cardiac events in patients after MI. The data presented herein show that IgG aCL antibodies in the highest quartile represent an independent risk factor for recurrent MI and cardiac death, with an HR of 1.63 after adjusting for other relevant clinical variables. This risk is comparable to other known risk factors for recurrent coronary events in our study: prior MI (HRϭ1.77), non-insulin-dependent diabetes (HRϭ1.87), ejection fraction Յ30% (HRϭ1.69), and smoking (HRϭ1.81).
Our data also revealed an inverse association of IgM aCL antibody levels with recurrent cardiac events. Thus, patients with elevated IgG aCL and low IgM aCL antibodies had the highest risk compared with all other aCL antibody groups.
The association between myocardial infarction and IgG aCL antibodies has been suggested in several smaller studies. [11] [12] [13] With regard to noncardiac events, IgG aCL antibod- 
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ies at levels above the 95th percentile have been implicated as a significant risk factor for venous thrombosis or pulmonary embolus in a case-control study from the Physicians' Health Study 2 and for first stroke in a large case-control study. 3 In other studies that found a positive association of the IgG aCL antibodies with arterial thrombosis, information about the IgM aCL antibodies was not reported 19 or the association was not conclusive. 8 Our study, because of its large size, had the power to detect such an association. Before our study, minimal information was available regarding the association between a␤ 2 GPI antibodies and coronary events. We found no association between these antibodies (either IgG or IgM) with recurrent cardiac events despite a meaningful correlation (rϭ0.50) between aCL IgM and a␤ 2 GPI IgM antibodies. Our findings confirm and extend the only relevant study available in which only the IgG isotype was measured. 20 This result is consistent with Vaarala's 21 observation that a␤ 2 GPI antibodies are infrequently detected in nonautoimmune patients with MI.
The question of whether aCL antibodies can be induced in response to tissue necrosis that occurs in MI is still unresolved. 22 However, there is clinical evidence that aCL antibodies precede the development of first MI 12 and that aCL antibody titers are stable for up to 3 months after MI. 11 These studies indicate that aCL antibodies are not generated by tissue necrosis but rather they participate in the pathogenesis of MI. This hypothesis is biologically plausible because of the proinflammatory [23] [24] [25] and procoagulant 26 -29 properties of these antibodies. The aCL autoantibodies detected in SLE are primarily directed against the so-called "cofactor proteins," including ␤ 2 GPI (the predominant cofactor), prothrombin, annexin V, thrombomodulin, and proteins C and S, among others. 26, 30 Such cofactors share the property of being phospholipid-binding proteins with intrinsic anticoagulant activity. Hence, binding of aCL antibodies may diminish the function of these anticoagulant systems. In addition, IgG aCL antibodies enhance platelet activation and thromboxane production 27 and activate endothelial cells in the presence of ␤ 2 GPI. 28, 29 The interplay among aCL antibodies, the anticoagulant system, and the endothelial cells could contribute to the prothrombotic state that is central to the pathogenesis of recurrent MI. 16, 31 A unique finding of our study is the reverse association of the IgM aCL antibodies with recurrent cardiac events, even in the presence of IgG aCL antibodies. Several non-mutually exclusive mechanisms could account for this observation. IgM aCL antibodies might represent protective natural autoantibodies 32 or they could have rheumatoid factor activity and thus play a beneficial role in immune homeostasis. 33 Alternatively, it could be postulated that the aCL antibody response in our patients starts with a primary IgM antibody response against nonpathogenic epitopes that subsequently, through epitope spreading, results in the recognition of previously ignored pathogenic epitopes by antigen-selected IgG antibodies. 34 A hypothetical example of a protective initial IgM antibody response might be the binding and inhibition of the colonization of the vascular endothelium by infectious agents such as Chlamydia pneumoniae that may play a role in the development of atherosclerosis. 35, 36 The ability of aCL antibodies to recognize chlamydial antigens, or conversely, the ability of chlamydial infection to elicit aCL antibodies, remains to be tested. This model is appealing because it is also consistent with the lack of association of recurrent coronary events with a␤ 2 GPI antibodies that was observed in our study. Indeed, aCL antibodies induced by infections do not recognize ␤ 2 GPI, 37 and these antibodies may be prevalent in our cohort of nonautoimmune patients.
It should be noted that aCL antibodies cross-react with oxidized LDL 25 and that antibodies against oxidized LDL have been implicated in the development of atherosclerosis. 22 When considered that both C pneumoniae and chlamydial hsp60, an inflammatory antigen that was recently localized in atheromas, can induce cellular oxidation of LDL, 38 a reasonable link between chlamydial infection, aCL antibodies, and atherosclerosis emerges.
In summary, IgG aCL antibodies are an independent risk factor for recurrent cardiac events in this large population of nonautoimmune patients. Our findings contribute new data in the ongoing research for identification of additional coronary risk factors. 39 At present, the use of IgG aCL antibodies to stratify patients for coronary risk is limited by the heterogeneity of these antibodies, 40 the available commercial kits, 41 and the lack of standardization of the aCL antibody assays between the different laboratories. 42 As we learn more about the different specificities of the aCL antibodies and more standardized assays develop, aCL antibodies may become useful for identifying patients at risk for coronary events. Although high levels IgG and low levels of IgM aCL antibodies convey independent risk, the predictive value of these antibodies is too low for use in risk-stratification application at this time.
